Metraipolis › archive › dc_d5dd00a026ae

Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study — Europe PMC PMID:42526181

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42526181
DOI: 10.1016/j.breast.2026.104888
License (as archived): solo-consultazione
Archived: 2026-10-17T19:25:19.972Z
SHA-256 of the archived text: f50ce49159acd4c2b44688d8052d16015372ced4ec6443a4e8d76052aed6bd2e
Stable URL of this page: https://metraipolis.com/documento/dc_d5dd00a026ae

How to cite

Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study — Europe PMC PMID:42526181 — Europe PMC (en), https://europepmc.org/article/MED/42526181 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d5dd00a026ae (Metraipolis archive dc_d5dd00a026ae, sha256 f50ce49159acd4c2b44688d8052d16015372ced4ec6443a4e8d76052aed6bd2e)

BibTeX

@misc{dcd5dd00a026ae,
  title = {Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study — Europe PMC PMID:42526181},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42526181},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d5dd00a026ae; sha256 f50ce49159acd4c2b44688d8052d16015372ced4ec6443a4e8d76052aed6bd2e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42526181. Agents can read the archived copy with the MCP tool read_document.